NHI to reimburse Reminyl for additional indications from Feb.

Published: 2006-02-09 06:58:00

Updated: 2006-02-09 06:58:00

The NHI reimbursement for the additional indications of Reminyl, an anti-schizophrenia drug, will be effected from Feb. 1 covering the Alzheimer disease patients with cerebral vascular conditions according to the revised ordinance of "Standards for NHI payment application and its detailed particu...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK